<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00873353</url>
  </required_header>
  <id_info>
    <org_study_id>ML21154</org_study_id>
    <secondary_id>2007-003206-96</secondary_id>
    <nct_id>NCT00873353</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients</brief_title>
  <acronym>XELTA</acronym>
  <official_title>An Open Non-randomized Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Tarceva in Combination With Capecitabine in Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Gallego de Investigaciones Oncologicas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Gallego de Investigaciones Oncologicas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy of the treatment with erlotinib in&#xD;
      combination with capecitabine in patients with advanced pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This efficacy will be determined by objective response rate following RECIST criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate following RECIST criteria</measure>
    <time_frame>within study period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>within study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 months survival rate</measure>
    <time_frame>within first 6 months after study inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Time from study inclusion to disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (TTF)</measure>
    <time_frame>Time from study inclusion to treatment failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the index of clinical benefit</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and tolerability of erlotinib and capecitabine when administered together</measure>
    <time_frame>Within study period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Metastatic Adenocarcinoma of the Pancreas</condition>
  <arm_group>
    <arm_group_label>Unique arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles (3 weeks each one) of :&#xD;
capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks&#xD;
erlotinib (Tarceva®) 150mg/day, oral. Days: every days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine + erlotinib</intervention_name>
    <description>6 cycles (3 weeks each one) of :&#xD;
capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks&#xD;
erlotinib (Tarceva®) 150mg/day, oral. Days: every days</description>
    <arm_group_label>Unique arm</arm_group_label>
    <other_name>capecitabine (Xeloda®)y erlotinib (Tarceva®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and willingness to sign a written informed consent&#xD;
&#xD;
          2. Informed consent signed by the patient&#xD;
&#xD;
          3. Age &gt; 18 years old&#xD;
&#xD;
          4. Able to fulfill all criteria from the protocol&#xD;
&#xD;
          5. Performance status Karnofsky ≥ 60% (ECOG 0-2)&#xD;
&#xD;
          6. Life expectancy ≥ 12 weeks&#xD;
&#xD;
          7. Histologically or cytological (excluding endocrine pancreatic tumour), with metastatic&#xD;
             (stage IV), following 6th edition of TNM classification&#xD;
&#xD;
          8. Measurable disease following RECIST criteria&#xD;
&#xD;
          9. Adequate bone marrow function as determined by:&#xD;
&#xD;
               -  Absolute Neutrophil account (ANC) ≥ 1,5 x 109/L&#xD;
&#xD;
               -  Platelets: ≥ 100 x 109/L&#xD;
&#xD;
               -  Hemoglobin: ≥ 9 g/dL.&#xD;
&#xD;
         10. Adequate liver function, as determined by:&#xD;
&#xD;
               -  Serum bilirubin (total): ≤ 1,5 x LSN&#xD;
&#xD;
               -  AST, ALT ≤ 2,5 x LSN in patients without liver metastasis. In patients with liver&#xD;
                  metastasis ≤ 5 x LSN&#xD;
&#xD;
         11. Adequate renal function, as determined by:&#xD;
&#xD;
               -  Clearance creatinine &gt; 60.0 ml/min&#xD;
&#xD;
         12. Men or women potentially fertile (including postmenopausal women amenorrheic at least&#xD;
             24 months before the study) should use adequate contraceptive methods (oral&#xD;
             contraceptives, intrauterine disposal, barrier methods together with spermicide or&#xD;
             surgery sterilization)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Local pancreatic cancer (stage IA-IIB) or locally advance cancer (stage III),&#xD;
             following the TNM 6th edition classification. Patients with metastatic disease that&#xD;
             relapse after the initial diagnosis of local or advance disease could be included in&#xD;
             this study.&#xD;
&#xD;
          2. Evidence of medullary compression, carcinomatosis meningitis or brain metastasis. In&#xD;
             case of clinical suspicious of brain metastasis is mandatory to perform a brain TAC/MR&#xD;
             4 weeks prior inclusion.&#xD;
&#xD;
          3. Previous systemic treatment for metastasis pancreas cancer. Adjuvant chemotherapy is&#xD;
             permitted ≥ 4 weeks prior de inclusion. All toxicities from the adjuvant treatment&#xD;
             must been solve before the inclusion and should be confirmed the diseases progression&#xD;
             (metastatic disease) alter adjuvant treatment&#xD;
&#xD;
          4. Primary tumours Developer 5 years previous to the inclusion, except in situ cérvix&#xD;
             carcinoma or skin basocellular cancer properly treated&#xD;
&#xD;
          5. Non-controlled hypertension or cardiovascular disease clinically significant (active):&#xD;
&#xD;
               -  Cerebrovascular accident/ictus (≤ 6 weeks prior to inclusion)&#xD;
&#xD;
               -  Heart attack (≤ 6 months prior to inclusion)&#xD;
&#xD;
               -  Instable angina&#xD;
&#xD;
               -  Congestive cardiac insufficiency (grade II or superior following to New York&#xD;
                  Heart Association (NYHA)&#xD;
&#xD;
               -  Severe cardiac arrhythmia that require medication&#xD;
&#xD;
          6. Significant ophthalmology anomalies&#xD;
&#xD;
          7. Deficit in dihydropyrimidine dehydrogenase (DPD)&#xD;
&#xD;
          8. Unable to take oral drug. Previous surgical process that affect the absorption or make&#xD;
             the needed to have intravenous feeding or parenteral nutrition with lipids.&#xD;
&#xD;
          9. Pregnancy women or in latency period. Negative pregnancy test needed 7 days prior to&#xD;
             initiation drug study&#xD;
&#xD;
         10. Actual or 30 days previous to study treatment with other investigational drug or&#xD;
             participation in other trial&#xD;
&#xD;
         11. Previous treatment with Capecitabine or EGFR inhibitor.&#xD;
&#xD;
         12. Any other disease, metabolic disease&#xD;
&#xD;
         13. Known hypersensibility to any study drug or any of their component, or to&#xD;
             5-fluorouracile&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafel López López, Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Grupo Gallego de Investigaciones Oncológicas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide</name>
      <address>
        <city>Ferrol</city>
        <state>La Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de La Coruña</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>La Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Xeral Calde</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Orense</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Xeral Cies</name>
      <address>
        <city>Vigo</city>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital POVISA</name>
      <address>
        <city>Vigo</city>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>March 31, 2009</study_first_submitted>
  <study_first_submitted_qc>March 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2009</study_first_posted>
  <last_update_submitted>August 17, 2010</last_update_submitted>
  <last_update_submitted_qc>August 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rafael López López</name_title>
    <organization>Grupo Gallego de Investigaciones Oncologicas</organization>
  </responsible_party>
  <keyword>Metastatic Adenocarcinoma of the Pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 12, 2015</submitted>
    <returned>March 25, 2015</returned>
    <submitted>February 22, 2016</submitted>
    <returned>March 21, 2016</returned>
    <submitted>March 29, 2016</submitted>
    <returned>April 29, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

